Cheek Augmentation
0
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
GaldermaTX - Dallas
3 programsGAL1704N/A1 trial
Restylane Lyft with LidocaineN/A1 trial
Restylane VolymeN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GaldermaRestylane Volyme
GaldermaGAL1704
GaldermaRestylane Lyft with Lidocaine
Clinical Trials (3)
Total enrollment: 390 patients across 3 trials
Study to Evaluate Satisfaction After Treatment With Restylane
Start: Apr 2021Est. completion: Aug 202160 patients
N/ACompleted
GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies
Start: Oct 2018Est. completion: May 2020270 patients
N/ACompleted
Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation
Start: May 2017Est. completion: Oct 201760 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.